Leo Pharma on Tuesday said it will acquire the rights to dersimelagon, an experimental medicine from that’s undergoing Food and Drug Administration review, in a deal potentially worth hundreds of millions of dollars. If approved, the medicine would be the first oral treatment for two skin conditions known as erythropoietic protoporphyria and X-linked protoporphyria, Leo said. The rare genetic diseases cause severe reactions to the sun; patients can experience burning sensations, rashes, swellin

Eli Lilly has tapped OmniAb and its antibody discovery engine for an ion channel-focused collaboration. While the deal is light on details, the California-based research firm will receive an undisclosed upfront payment and is eligible for up to $370 million in R&D and commercial milestones, plus tiered royalties. The licensing agreement covers a new ion channel programme with an undisclosed target and modality, though it's likely to be antibody-based given OmniAb specialises in antibody discove

Khartis said the financing would support its pipeline of oral small molecule medicines targeting immunology pathways. Credit: Maryia Blizniakova/Shutterstock.com. Armed with $95m in funding and a former Pfizer drug discovery specialist, Khartis Therapeutics has emerged with the aim of bringing a new treatment for an autoimmune disease that causes eye inflammation. Unveiling itself via a $50m Series B raise announcement, Khartis said its pipeline includes oral small-molecule medicines with both

Aizen Therapeutics inked a multi-programme collaboration with an undisclosed, publicly listed San Diego-based biotech to design oral peptide therapeutics. The deal, announced over the weekend, grants Aizen several million in initial revenue, alongside milestone payments of up to $100 million for each chosen target. The latest partnership will employ Aizen's DaX foundation model to develop oral peptides targeting conditions across immunology and neurology. According to the AI-native firm, DaX —

Multi-program deal with revenue potential of $100 million per target Aug. 15, 2026 -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to design oral peptide therapeutics using its DaX™ foundation model. The agreement provides Aizen with several million dollars in initial revenue and up to $100 million in milestones for each nominated target. "Oral biologics represent

After its last attempt at a merger failed in 2023, Redx Pharma seems to have found a willing partner in Skye Bioscience, which experienced a couple of trial failures in recent years. The public biotech has entered into an agreement to combine with privately held fibrotic disease company Redx in a deal that will net $125 million in financing for a new public company called Fibrx Therapeutics. The deal mirrors the structure of a reverse merger. The combined firm will be led by Redx’s current lead

China-based IASO Biotechnology has completed the acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering company, adding a proprietary T-cell fratricide-prevention platform and a Phase I clinical asset targeting CD7-positive T-cell malignancies to its existing CAR-T portfolio. The deal extends IASO Bio's cell therapy footprint beyond its approved anti-BCMA product into hematologic indications where conventional CAR-T approaches have been technically constrained. Financial

A novel diagnostic agent to identify patients with tau neurofibrillary tangles (NFTs), including NFTs isolated to the medial temporal lobe Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, also previously referred to as MK-6240), a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to i

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment Aug. 10, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up t

Aug. 10, 2026 -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in